Vericel Corporation (ATQP.F)

25.94 +0.59 (+2.33%) At close: 08:02AM CET

Vericel Corporation

64 Sidney Street
Cambridge, MA 02139
United States
617 588 5555
https://vcel.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 281

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Dominick C. Colangelo Esq.	CEO, Pres & Director	1.36M	1.68M	1964
Mr. Joseph Anthony Mara Jr.	CFO & Treasurer	636.24k	N/A	1976
Mr. Michael Halpin	Chief Operating Officer	672.86k	2.2M	1961
Mr. Sean C. Flynn	Sr. VP, Gen. Counsel & Sec.	556.66k	749.18k	1974
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.	Chief Medical Officer	578.36k	1.95M	1962
Mr. Jonathan Siegal	Principal Accounting Officer, VP & Corp. Controller	N/A	N/A	N/A
Mr. Eric Burns	Exec. Director of Financial Planning and Analysis & Investor Relations	N/A	N/A	N/A
Mr. Patrick J. Fowler	Sr. VP of Corp. Devel. & Strategy	N/A	N/A	N/A
Ms. Heidi Hassen	VP of HR	N/A	N/A	N/A
Mr. Roland DeAngelis	Sr. VP of Commercial Operations	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Vericel Corporation’s ISS Governance QualityScore as of January 28, 2023 is 4. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 4; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.